Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1990-08-01
1992-06-30
Bond, Robert T.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514312, 546153, 546170, 546174, C07D21514, C07D21518, C07D21520, A61K 3147
Patent
active
051263548
ABSTRACT:
Inhibiting leucotriene synthesis in patients with novel disubstituted (quinolin-3-yl-methoxy)phenylacetic acid derivatives of the formula ##STR1## in which A, B, D, E, G, K and M each independently is H, OH, halogen, CF.sub.3, OCF.sub.3, COOH, alkyl, alkoxycarbonyl or aryl,
REFERENCES:
patent: 4661499 (1987-04-01), Young et al.
patent: 4929626 (1990-05-01), Mohrs et al.
Musser, et al. J. Med. Chem. 1990 33 240-245.
Journal of the Chemical Society Chemical Communications, Jun. 7, 1972, JCCCAR (11) 625-704 (1972).
Chemische Berichte, Gegrundet 1868, G. E. Jeromin, W. Orth, B. Rapp, W. Weiss. Chem. Ber. 120, 649-651 (1987).
Fruchtmann Romanis
Kohlsdorfer Christian
Mohrs Klaus
Muller-Peddinghaus Reiner
Raddatz Siegfried
Bayer Aktiengesellschaft
Bond Robert T.
Ward E. C.
LandOfFree
Leukotriene synthesis-inhibiting disubstituted (quinolin-2-yl-me does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Leukotriene synthesis-inhibiting disubstituted (quinolin-2-yl-me, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Leukotriene synthesis-inhibiting disubstituted (quinolin-2-yl-me will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1864049